Sands Capital Management 13F holdings, Q3 2010
Holdings as of September 30, 2010 · filings on SEC EDGAR · latest filing →
Sands Capital Management disclosed 45 US equity positions worth $11.9bn in its Q3 2010 13F filing. The largest position was AMZN at 8.6% of the reported book, followed by CRM and QCOM. Against the Q2 2010 filing, it opened 4 new positions, added to 8 and reduced 30 among the top 45 holdings.
What did Sands Capital Management own in Q3 2010? Top 45 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2010 |
|---|---|---|---|---|---|---|---|
| 1 | AMZN AMAZON.COM | Consumer Cyclical | 8.6% | $1.0bn | 6,541,672 | -2% | reduced |
| 2 | CRM SALESFORCE.COM | Technology | 7.9% | $934.1m | 8,354,659 | -2% | reduced |
| 3 | QCOM QUALCOMM | Technology | 7.6% | $905.7m | 20,068,587 | -2% | reduced |
| 4 | AAPL APPLE | Technology | 6.9% | $817.1m | 2,879,769 | -25% | reduced |
| 5 | V VISA INC | Financial Services | 6.6% | $779.2m | 10,493,065 | 13% | added |
| 6 | 5.4% | $647.6m | 1,231,766 | -2% | reduced | ||
| 7 | NATIONAL OILWELL VARCO | 5.4% | $646.8m | 14,544,168 | -1% | reduced | |
| 8 | ALLERGAN | 4.7% | $556.9m | 8,370,173 | 1% | added | |
| 9 | FMC TECHNOLOGIES | 4.3% | $516.1m | 7,558,034 | -4% | reduced | |
| 10 | SLB SCHLUMBERGER | Energy | 4.1% | $490.3m | 7,958,890 | -2% | reduced |
| 11 | GENZYME | 3.8% | $446.4m | 6,306,517 | -36% | reduced | |
| 12 | ILMN ILLUMINA INC | Healthcare | 3.7% | $444.9m | 9,042,472 | -2% | reduced |
| 13 | INTERCONTINENTAL EXCHANGE | 3.7% | $437.5m | 4,178,221 | -1% | reduced | |
| 14 | NKE NIKE | Consumer Cyclical | 3.5% | $420.6m | 5,248,901 | -2% | reduced |
| 15 | VARIAN MEDICAL SYSTEMS | 3.0% | $360.2m | 5,953,574 | -2% | reduced | |
| 16 | SCHW CHARLES SCHWAB | Financial Services | 2.9% | $346.4m | 24,923,607 | 28% | added |
| 17 | STAPLES | 2.8% | $336.6m | 16,087,956 | 33% | added | |
| 18 | LVS LAS VEGAS SANDS | Consumer Cyclical | 2.8% | $329.9m | 9,466,481 | -24% | reduced |
| 19 | GWW WW GRAINGER INC | Industrials | 2.5% | $293.8m | 2,466,271 | -1% | reduced |
| 20 | PXGBX PRAXAIR, INC | 2.3% | $276.7m | 3,065,750 | – | new | |
| 21 | ASML | 2.2% | $256.4m | 8,624,571 | – | new | |
| 22 | FFIV F5 NETWORKS INC | Technology | 1.4% | $160.9m | 1,549,566 | – | new |
| 23 | FLIR FLIR SYSTEMS INC | 1.3% | $148.6m | 5,781,480 | -2% | reduced | |
| 24 | ALXN ALEXION PHARMACEUTICALS INC | 1.2% | $139.5m | 2,167,455 | 24671% | added | |
| 25 | CME CME GROUP | Financial Services | 0.5% | $58.5m | 224,734 | -74% | reduced |
| 26 | MELI MERCADOLIBRE | Consumer Cyclical | 0.3% | $30.5m | 422,155 | -21% | reduced |
| 27 | MINDRAY MEDICAL INTL | 0.2% | $27.2m | 918,575 | -6% | reduced | |
| 28 | ABBNY ABB LTD | Industrials | 0.2% | $22.4m | 1,060,300 | 0% | held |
| 29 | TSM TAIWAN SEMICONDUCTOR MFG ADS | Technology | 0.1% | $15.9m | 1,563,280 | 0% | held |
| 30 | BMRN BIOMARIN PHARMS | Healthcare | 0.0% | $1.8m | 80,425 | 17% | added |
| 31 | NUVASIVE | 0.0% | $1.6m | 45,975 | 32% | added | |
| 32 | CELG CELGENE | 0.0% | $994.0k | 17,250 | -3% | reduced | |
| 33 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 0.0% | $913.0k | 13,620 | -24% | reduced |
| 34 | ST. JUDE MEDICAL | 0.0% | $905.0k | 23,000 | -3% | reduced | |
| 35 | DENTSPLY INTL | 0.0% | $850.0k | 26,600 | -3% | reduced | |
| 36 | HUMAN GENOME SCIENCES | 0.0% | $643.0k | 21,600 | -3% | reduced | |
| 37 | ATHENAHEALTH, INC | 0.0% | $599.0k | 18,150 | -2% | reduced | |
| 38 | SEATTLE GENETICS INC | 0.0% | $492.0k | 31,700 | -3% | reduced | |
| 39 | VRTX VERTEX PHARMS | Healthcare | 0.0% | $490.0k | 14,175 | -3% | reduced |
| 40 | DENDREON | 0.0% | $450.0k | 10,925 | -3% | reduced | |
| 41 | MNTA MOMENTA PHARMACEUTICALS INC | 0.0% | $310.0k | 20,625 | – | new | |
| 42 | CSCO CISCO SYSTEMS | Technology | 0.0% | $307.0k | 14,000 | 0% | held |
| 43 | ISIS PHARMACEUTICAL | 0.0% | $301.0k | 35,800 | -2% | reduced | |
| 44 | VIVUS INC | 0.0% | $278.0k | 41,625 | 2% | added | |
| 45 | ALNY ALNYLAM PHARMS | Healthcare | 0.0% | $255.0k | 20,775 | -3% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.